{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,10]],"date-time":"2026-05-10T20:15:13Z","timestamp":1778444113825,"version":"3.51.4"},"reference-count":19,"publisher":"Termedia Sp. z.o.o.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reumatologia"],"published-print":{"date-parts":[[2019,2,28]]},"abstract":"<jats:p>Systemic sclerosis is an autoimmune connective tissue disease affecting both skin and internal organs. Progressive disease with multiple organ involvement is considered to have a poor prognosis. Treatment possibilities are limited, but certain patients may benefit from autologous hematopoietic stem cell transplantation (auto-HSCT).&lt;br \/&gt;\nWe report a case of a 30-year-old woman with progressive diffuse systemic sclerosis treated with parenteral cyclophosphamide with unsatisfactory results. Due to progression of the disease and lack of alternative therapies auto-HSCT was performed.&lt;br \/&gt;\nAfter instituting treatment with autologous hematopoietic stem cell transplantation no immunosuppressive therapy has been required during 5-year follow-up. Improvement in exertion tolerance, partial regression of skin lesions and stabilization of pulmonary and cardiovascular changes were observed. Currently therapeutic options in patients with progressive systemic sclerosis are limited. Hematopoietic stem cell transplantation might become an alternative therapeutic solution not only in the early phase of the disease but also among selected patients with progressive systemic sclerosis resistant to standard therapy.<\/jats:p>","DOI":"10.5114\/reum.2019.83240","type":"journal-article","created":{"date-parts":[[2019,3,11]],"date-time":"2019-03-11T08:04:46Z","timestamp":1552291486000},"page":"50-54","source":"Crossref","is-referenced-by-count":5,"title":["Autologous hematopoietic stem cell transplant for progressive diffuse systemic sclerosis: procedural success and clinical outcome in 5-year follow-up"],"prefix":"10.5114","volume":"57","author":[{"given":"Katarzyna","family":"Pawlak-Bu\u015b","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wiktor","family":"Schmidt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Micha\u0142","family":"Olejarz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Czy\u017c","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mieczys\u0142aw","family":"Komarnicki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piotr","family":"Leszczy\u0144ski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3061","published-online":{"date-parts":[[2019,2,28]]},"reference":[{"key":"ref-775625","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11926-007-0008-z","article-title":"New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma","volume":"9","author":"Abraham DJ","year":"2007","unstructured":"Abraham DJ, Eckes B, Rajkumar V, et al. (2007). New developments in fibroblast and myofibroblast biology: implications for fibrosis and scleroderma Curr Rheumatol Rep. 9: 136-143.","journal-title":"Curr Rheumatol Rep"},{"key":"ref-775626","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1146\/annurev-pathol-011110-130312","article-title":"The Pathogenesis of Systemic Sclerosis","volume":"6","author":"Katsumoto RT","year":"2011","unstructured":"Katsumoto RT, Whitfield ML, Connolly MK. (2011). The Pathogenesis of Systemic Sclerosis Annu Rev Pathol. 6: 509-537.","journal-title":"Annu Rev Pathol"},{"key":"ref-775627","doi-asserted-by":"crossref","first-page":"2737","DOI":"10.1002\/art.38098","article-title":"2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative","volume":"65","author":"van den","year":"2013","unstructured":"van den Hoogen F, Khanna D, Fransen J, et al. (2013). 2013 Classification Criteria for Systemic Sclerosis: An American College of Rheumatology\/European League Against Rheumatism Collaborative Initiative Arthritis Rheum. 65: 2737-2747.","journal-title":"Arthritis Rheum"},{"key":"ref-775628","first-page":"1573","article-title":"Criteria for the classification of early systemic sclerosis","volume":"28","author":"LeRoy EC","year":"2001","unstructured":"LeRoy EC, Medsger TA. (2001). Criteria for the classification of early systemic sclerosis J Rheumatol. 28: 1573-1576.","journal-title":"J Rheumatol"},{"key":"ref-775629","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1136\/annrheumdis-2016-209768","article-title":"The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index","volume":"76","author":"Valentini G","year":"2017","unstructured":"Valentini G, Iudici M, Walker UA, et al. (2017). The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index Ann Rheum Dis. 76: 270-276.","journal-title":"Ann Rheum Dis"},{"key":"ref-775630","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1002\/art.38390","article-title":"Prediction of pulmonary complications and long-term survival in systemic sclerosis","volume":"66","author":"Nihtyanova SI","year":"2014","unstructured":"Nihtyanova SI, Schreiber BE, Ong VH, et al. (2014). Prediction of pulmonary complications and long-term survival in systemic sclerosis Arthritis Rheumatol. 66: 1625-1635.","journal-title":"Arthritis Rheumatol"},{"key":"ref-775631","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database","volume":"69","author":"Tyndall AJ","year":"2010","unstructured":"Tyndall AJ, Bannert B, Vonk M, et al. (2010). Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Ann Rheum Dis. 69: 1809-1815.","journal-title":"Ann Rheum Dis"},{"key":"ref-775632","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/sj.bmt.1700727","article-title":"Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT)","volume":"19","author":"Tyndall A","year":"1997","unstructured":"Tyndall A, Gratwohl A. (1997). Blood and marrow stem cell transplants in auto-immune disease: a consensus report written on behalf of the European League against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) Bone Marrow Transplant. 19: 643-645.","journal-title":"Bone Marrow Transplant"},{"key":"ref-775633","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt RK","year":"2011","unstructured":"Burt RK, Shah SJ, Dill K, et al. (2011). Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial Lancet. 378: 498-506.","journal-title":"Lancet"},{"key":"ref-775634","doi-asserted-by":"crossref","first-page":"2490","DOI":"10.1001\/jama.2014.6368","article-title":"Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial","volume":"311","author":"van Laar","year":"2014","unstructured":"van Laar JM, Farge D, Sont JK, et al. (2014). Autologous hematopoietic stem cell transplantation vs intravenous pulse cyclophosphamide in diffuse cutaneous systemic sclerosis: a randomized clinical trial JAMA. 311: 2490-2498.","journal-title":"JAMA"},{"key":"ref-775635","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/BOR.0b013e32834aa45f","article-title":"Hematopoietic stem cell transplantation for systemic sclerosis: history and current status","volume":"23","author":"Burt RK","year":"2011","unstructured":"Burt RK, Milanetti F. (2011). Hematopoietic stem cell transplantation for systemic sclerosis: history and current status Curr Opin Rheumatol. 23: 519-529.","journal-title":"Curr Opin Rheumatol"},{"key":"ref-775636","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1038\/bmt.2011.185","article-title":"Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation","volume":"47","author":"Snowden JA","year":"2012","unstructured":"Snowden JA, Saccardi R, Allez M, et al. (2012). Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation Bone Marrow Transplant. 47: 770-790.","journal-title":"Bone Marrow Transplant"},{"key":"ref-775637","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/01.bor.0000434669.32150.ac","article-title":"Stem cell transplantation in systemic sclerosis","volume":"25","author":"van Laar","year":"2013","unstructured":"van Laar JM, Sullivan K. (2013). Stem cell transplantation in systemic sclerosis Curr Opin Rheumatol. 25: 719-725.","journal-title":"Curr Opin Rheumatol"},{"key":"ref-775638","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S0140-6736(12)62114-X","article-title":"Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis","volume":"381","author":"Burt RK","year":"2013","unstructured":"Burt RK, Oliveira MC, Shah SJ, et al. (2013). Cardiac involvement and treatment-related mortality after non-myeloablative haemopoietic stem-cell transplantation with unselected autologous peripheral blood for patients with systemic sclerosis: a retrospective analysis Lancet. 381: 1116-1124.","journal-title":"Lancet"},{"key":"ref-775639","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1136\/annrheumdis-2016-209909","article-title":"Update of EULAR recommendations for the treatment of systemic sclerosis","volume":"76","author":"Kowal-Bielecka O","year":"2017","unstructured":"Kowal-Bielecka O, Fransen J, Avouac J, et al. (2017). Update of EULAR recommendations for the treatment of systemic sclerosis Ann Rheum Dis. 76: 1327-1339.","journal-title":"Ann Rheum Dis"},{"key":"ref-775640","volume-title":"Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial (ASSIST IIb)","author":"Northwestern University","year":"2000-2017","unstructured":"Northwestern University. (2000-2017). Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial (ASSIST IIb).  U. S. National Library of Medicine, Bethesda.  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01445821. Available from: ."},{"key":"ref-775641","volume-title":"Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis (AST-MOMA)","author":"University Hospital","year":"2000-2017","unstructured":"University Hospital Tuebingen. (2000-2017). Autologous Stem Cell Transplantation for Progressive Systemic Sclerosis (AST-MOMA).  U. S. National Library of Medicine, Bethesda.  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01895244. Available from: ."},{"key":"ref-775642","volume-title":"Scleroderma Treatment With Autologous Transplant (STAT) Study","author":"Fred Hutchinson","year":"2000-2017","unstructured":"Fred Hutchinson Cancer Research Center. (2000-2017). Scleroderma Treatment With Autologous Transplant (STAT) Study.  U. S. National Library of Medicine, Bethesda.  https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01314100. Available from: ."},{"key":"ref-775643","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1038\/bmt.2017.56","article-title":"Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners","volume":"52","author":"Farge D","year":"2017","unstructured":"Farge D, Burt RK, Oliveira MC, et al. (2017). Cardiopulmonary assessment of patients with systemic sclerosis for hematopoietic stem cell transplantation: recommendations from the European Society for Blood and Marrow Transplantation Autoimmune Diseases Working Party and collaborating partners Bone Marrow Transplant. 52: 1495-1503.","journal-title":"Bone Marrow Transplant"}],"container-title":["Rheumatology"],"original-title":["Wyniki leczenia pacjentki z post\u0119puj\u0105c\u0105 twardzin\u0105 uk\u0142adow\u0105 przeszczepem autologicznych kom\u00f3rek krwiotw\u00f3rczych w 5-letniej obserwacji klinicznej"],"link":[{"URL":"https:\/\/reu.termedia.pl\/pdf-102823-85788","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/reu.termedia.pl\/pdf-102823-85788","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,27]],"date-time":"2023-01-27T08:09:03Z","timestamp":1674806943000},"score":1,"resource":{"primary":{"URL":"https:\/\/reu.termedia.pl\/Autologous-hematopoietic-stem-cell-transplant-for-progressive-diffuse-systemic-sclerosis,102823,0,2.html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,28]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"alternative-id":["102823"],"URL":"https:\/\/doi.org\/10.5114\/reum.2019.83240","relation":{},"ISSN":["0034-6233","2084-9834"],"issn-type":[{"value":"0034-6233","type":"print"},{"value":"2084-9834","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,2,28]]}}}